Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder) is a triple-combination preparation containing fluticasone furoate (an inhaled corticosteroid), umeclidinium bromide (an anticholinergic agent), and vilanterol (a long-acting β₂-agonist). It is specifically designed for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Indications for Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)

Chronic Obstructive Pulmonary Disease (COPD)

Trelegy Ellipta is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

COPD is a common disease characterized by persistent respiratory symptoms and airflow limitation, encompassing two phenotypes: chronic bronchitis and emphysema.

This medication can effectively improve dyspnea symptoms in COPD patients and reduce the frequency of acute exacerbations.

Asthma Treatment

Trelegy Ellipta is indicated for the maintenance treatment of asthma in patients aged 18 years and older.

The medication exerts a synergistic effect through three components with different mechanisms of action, providing comprehensive symptom control for asthma patients.

Usage Limitations

It is not indicated for status asthmaticus or other acute exacerbations of COPD or asthma that require intensive treatment.

It is contraindicated in patients with a severe allergic reaction to milk proteins or any component of the medication.

It is not indicated for the relief of acute bronchospasm.

Specifications and Properties of Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)

Dosage Specifications

100/62.5/25 mcg strength: Each inhalation contains 100 mcg of fluticasone furoate, 62.5 mcg of umeclidinium bromide, and 25 mcg of vilanterol. This is the only strength indicated for COPD treatment.

200/62.5/25 mcg strength: Each inhalation contains 200 mcg of fluticasone furoate, 62.5 mcg of umeclidinium bromide, and 25 mcg of vilanterol.

Drug Composition

Active ingredients: Fluticasone furoate (a synthetic trifluorinated corticosteroid), umeclidinium bromide (a long-acting muscarinic antagonist), and vilanterol (a long-acting β₂-adrenergic agonist).

Excipients: Lactose monohydrate (containing milk proteins) and magnesium stearate.

Physical Properties

Trelegy Ellipta is an orally inhaled powder, packaged in a light gray and beige plastic inhaler containing 2 aluminum foil blister strips.

Storage Methods for Trelegy Ellipta (Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol Trifenatate Inhalation Powder)

Storage Condition Requirements

Trelegy Ellipta should be stored at room temperature, specifically between 68°F and 77°F (20°C and 25°C), with short-term storage allowed within the range of 59°F to 86°F (15°C to 30°C).

The medication must be stored in a dry place, protected from direct heat or sunlight.

Handling Precautions

The medication should always be kept in the unopened moisture-proof aluminum foil blister and only removed before the first use.

Special attention should be paid to keeping it out of the reach of children to ensure safe storage of the medication.